Pharmaceutical CAS 198904-31-3 Atazanavir Intermediate Atazanavir Sulfate Powder Material Atazanavir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Atazanavir
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Atazanavir
• Name: Atazanavir Powder
• Appearance: White Powder
• Color: White Color
• Application: Pharmaceutical Intermediates
• Grade: Pharmaceutical Grade
• Specific: COA
• Assay: HPLC 99%
• Test Method: HPLC UV
• CAS: 198904-31-3
• Mf: C38h52n6o7
• MW: 704.869
• Density: 1.178g/Cm
• Melting Point: 207-209 C
• Refractive Index: 1.562
• Transport Package: Negotiable
• Specification: HPLC99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 3 Ton/Month

Product Description

Pharmaceutical CAS 198904-31-3 Atazanavir Intermediate Atazanavir Sulfate Powder Material Atazanavir

Product Description

Product Details

Product name	Atazanavir
CAS	198904-31-3
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Atazanavir is an azapeptide-based HIV-1 protease inhibitor. It selectively inhibits the specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thereby blocking the formation of mature virus. In vitro antiviral activity: The mean 50% inhibitory concentration (IC50) of atazanavir against a large number of laboratory and clinical isolates of HIV-1 virus strains hosted in peripheral blood monocytes, macrophages, CEM-SS cells and MT2 cells under human serum-free conditions was 2 to 5 nM.

Application & Function

1. Atazanavir is an inhibitor of HIV-1 protease (EC50 = 2.6 nM). In isolated cells, it has additive to moderately synergistic antiviral effects when combined with other antiretroviral drugs. As a result, it is commonly used in vivo in combination therapy for HIV-1 infection. Atazanavir competitively inhibits UDP-gluronosyltransferase, which conjugates bilirubin for clearance, leading to hyperbilirubinemia in a significant portion of those receiving atazanavir therapy.
2. Atazanavir is a novel azapeptide HIV protease inhibitor (PI). Antiviral.

Specification